Is Noninhaled Intranasal Carbon Dioxide Gas a Safe and Effective Treatment for Improvement of Nasal Symptoms of Allergic Rhinitis? by Couchara, Andrew R.
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2013
Is Noninhaled Intranasal Carbon Dioxide Gas a
Safe and Effective Treatment for Improvement of
Nasal Symptoms of Allergic Rhinitis?
Andrew R. Couchara
Philadelphia College of Osteopathic Medicine, andrewcou@pcom.edu
Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Allergy and Immunology Commons, and the Rehabilitation and Therapy Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Couchara, Andrew R., "Is Noninhaled Intranasal Carbon Dioxide Gas a Safe and Effective Treatment for Improvement of Nasal
Symptoms of Allergic Rhinitis?" (2013). PCOM Physician Assistant Studies Student Scholarship. Paper 128.
  
 
 
 
 
Is Noninhaled Intranasal Carbon Dioxide Gas a Safe and 
Effective Treatment for Improvement of Nasal Symptoms of 
Allergic Rhinitis? 
 
 
 
 
 
 
 
Andrew R. Couchara, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 
Philadelphia College of Osteopathic Medicine 
Philadelphia, Pennsylvania 
 
 
 
December 14, 2012 
 
 ABSTRACT 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not noninhaled intranasal 
carbon dioxide (CO2) gas is a safe and effective treatment for improvement of nasal symptoms of 
allergic rhinitis. 
 
STUDY DESIGN 
Systematic review of three randomized controlled trials published in 2008, 2011, and 2011. 
 
DATA SOURCES 
Three randomized controlled trials published after 2007 were obtained using PubMed. 
 
OUTCOMES MEASURED 
Number of sneezes and severity of nasal symptoms (nasal congestion, rhinorrhea) were recorded 
by subjects using an ordinal scale to obtain a Total Nasal Symptom Score (TNSS).  Scores 
recorded before and after treatment were compared to reflect effectiveness of treatment. 
 
RESULTS 
Casale TB, Romero FA, Spierings EL (2008) and Casale TB, Korenblat PE, Meltzer EO et al. 
(2011) demonstrated a high incidence of adverse events during gas administration – most 
commonly nasal stinging and watery eyes.  Baroody FM, Gavanescu L, Wang JH et al. (2011) 
did not record incidence of adverse events during gas administration.  Casale et al. (2008) 
reported a significant (>75%) improvement of nasal symptoms following treatment (26.7%) 
compared to placebo (3.4%).  Baroody et al. (2011) reported significant improvement in 
sneezing and rhinorrhea only. Casale et al. (2011) established significant improvement in total 
nasal symptoms in only one experimental arm when the treatment was administered at 
10mL/second x 10 seconds per nostril. 
 
CONCLUSION 
Evidence supporting the safety of noninhaled intranasal CO2 gas therapy is inconclusive at this 
time due to lack of research addressing administration more frequent than single-use.  Despite 
the high incidence of adverse events observed during single-use treatment, none of these effects 
were “serious” or “medically significant.”  Evidence supporting the efficacy of this therapy is 
inconclusive at this time due to lack of reproducibility beyond the preliminary study with 
adequate blinding. 
 
KEY WORDS 
allergic rhinitis, noninhaled intranasal carbon dioxide, safety, nasal symptoms 
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INTRODUCTION 
Allergic rhinitis (AR) affects approximately 20% of people in the United States1 as the 6th 
most common ailment.2  Annually, patients with AR average three additional primary care visits, 
fill nine more prescriptions, and cost the healthcare system $1,500 more than patients without 
AR leading to an estimated 5.3 billion dollars in healthcare costs per year.3  AR symptoms may 
significantly affect an individual’s quality of life and may contribute to other comorbidities 
including asthma, rhinosinusitis, and otitis.2,4 
Current methods of symptom-directed therapy include the gold standard of allergen 
avoidance as well as nonpharmacotherapy (i.e. saline nasal lavage), and pharmacotherapy 
including antihistamines, corticosteroids, sympathomimetics, antileukotrienes, allergen 
immunotherapy, and immunomodulators.2,4,5 With the exception of topical sympathomimetics 
(i.e. oxymetazoline /Afrin® nasal spray), no other current treatment for AR induces rapid relief 
from nasal symptoms.4  Even with topical sympathomimetics, use is limited to no more than 
three consecutive days due to the risk of developing subsequent rhinitis medicamentosa.4  Many 
individuals suffering from AR continue to have symptoms even after a combination of non-
pharmacological and pharmacological treatment methods have been exhausted.4 
Preliminary evidence suggests that noninhaled intranasal carbon dioxide gas may provide 
rapid relief from symptoms of AR.2  Using this method, CO2 gas is insufflated into one nostril at 
a time from compressed cylinders attached to tubing connected to a nosepiece.  The user holds 
their breath or exercises mouth breathing while gas passes over the nasal mucosa, through the 
nose and sinus cavities, and out through the contralateral nostril.2,4 
The current trend of healthcare strongly suggests that primary care offices will soon be 
faced with unprecedented patient volumes – a progression that warrants greater focus on cost 
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saving measures including more effective treatment options for common ailments.  If noninhaled 
intranasal CO2 proves to be effective, clinicians will need to need to understand and offer it to 
patients as an additional treatment option.  The combination of patient discomfort attributed to 
AR as well as increasing costs to the healthcare system deem research on this topic relevant to 
any physician, physician assistant, or nurse practitioner.  This paper reviews three randomized 
controlled trials comparing noninhaled intranasal CO2 gas therapy to placebo for safety and 
effectiveness of improvement of nasal symptoms of AR (nasal congestion, rhinorrhea, and 
sneezing). 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not noninhaled 
intranasal CO2 gas is a safe and effective treatment for improvement of nasal symptoms of AR. 
METHODS 
The search for relevant articles started December 20, 2011 and ended February 7, 2012.  
Articles found using PubMed were selected based on relevance to the clinical question as well as 
their focus on patient-oriented evidence that matters (POEM).  Keywords used to locate articles 
included, “allergic rhinitis,” “noninhaled intranasal carbon dioxide,” “safety,” and “nasal 
symptoms.”  Article inclusion criteria were limited to randomized controlled trials written in 
English that were published in peer-reviewed journals.  Exclusion criteria included studies that 
focused on participants under 18 years of age, studies that focused on disease-oriented evidence 
(DOE), and studies utilizing non-human models.  After inclusion and exclusion criteria were met 
and considered, three studies fulfilled these requirements.  They include: 1) Casale TB, Romero 
FA, Spierings EL (2008), a randomized, double-blind, placebo-controlled, parallel-group study; 
2) Baroody FM, Gavanescu L, Wang JH et al. (2011), a randomized, two-way crossover study; 
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and 3) Casale TB, Korenblat PE, Meltzer EO et al. (2011), a randomized, double-blind, placebo-
controlled, multicenter study. 
Relevant articles were selected according to similarity of population, intervention, 
method of comparison, outcomes measured, and study type as a randomized controlled trial.  The 
population was limited to otherwise healthy adults (18-75 years) with AR requiring 
pharmacotherapy.  Participants in all studies were either treated with noninhaled CO2 gas 
delivered intranasally or were given placebo (compressed room air or no gas at all).  Only Casale 
et al. (2008) used a true placebo by administering compressed room air via the treatment 
apparatus.  The comparison for the remaining two studies (Baroody et al. (2011) and Casale et al. 
(2011)) consisted of physically setting up the treatment apparatus to the subject’s nose without 
delivery of gas for a duration equivalent to each corresponding experimental arm’s duration of 
treatment.  All studies measured improvement of nasal symptoms (rhinorrhea, nasal congestion, 
and sneezing) following treatment.  
Casale et al. (2008) included POEM in the form of dichotomous data.  The two other 
studies used here included POEM as continuous data.  Statistics reported or used in these studies 
include p-values, relative risk reduction (RRR), absolute risk reduction (ARR), number needed 
to treat (NNT), absolute risk increase (ARI), number needed to harm (NNH), mean change from 
baseline, one-way analysis of variance (ANOVA), and analysis of covariance (ANCOVA).
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Table 1.  Demographics & Characteristics of Included Studies  
Study Type # pt Age Inclusion Criteria Exclusion Criteria W/D Intervention 
Casale 
et al. 
(2008) 
RCT; 
Randomized 
double-blind, 
placebo-
controlled, 
single-center, 
parallel 
group study 
89 18-
75 
• Adults with ≥ 2 year 
history of seasonal AR 
requiring 
pharmacotherapy 
• (+) skin prick test to 
seasonal grass or mold 
allergens prevalent in 
Omaha, 
Nebraska, in May 2005 
• Asthma (other than 
mild or intermittent) 
• Intranasal/inhaled/ 
systemic CS use 
within 30 days 
• Use of potentially 
confounding meds 
• Clinically 
significant nasal d/o 
• Hx URI within 14 
days 
• Rhinitis 
medicamentosa 
0 Noninhaled 
intranasal CO2 
gas admin’d 
at: 
10 mL/s x 60s 
per nostril 
from large-
capacity 
compressed 
gas cylinders 
Baroody 
et al. 
(2011)  
RCT; 
Randomized 
two-way 
crossover 
study; 
not blinded 
12 No 
data 
• Healthy adults  
• ± mild asthma req. 
only prn 
bronchodilators 
• (+) skin prick test to 
grass/ragweed 
• (+) screening 
challenge w/ two-fold 
incr. in 
ipsi/contralateral nasal 
secretions s/p allergen 
challenge  
• Subjects outside their 
allergy season 
• Asthma (other than 
mild or intermittent) 
• Use of any 
medications, 
antihistamines or 
LTRA ≥ 1 week,  
intranasal CS ≥ 1 
mo. before 
enrollment and for 
the duration of the 
study 
0 Noninhaled 
intranasal CO2 
gas admin’d 
at:  
8.33 mL/s x 
10s per nostril 
from large-
capacity 
compressed 
gas cylinders 
Casale 
et al. 
(2011)  
RCT 
Randomized 
double-blind, 
placebo-
controlled, 
multicenter, 
in-clinic 
study 
348 18-
65 
• Adults with ≥ 2 yr 
history of perennial AR 
requiring 
pharmacotherapy 
• (+) skin prick test to 
perennial allergen 
within the prior 12 mos. 
• Pts with TNSS ≥6 
• Asthma (other than 
mild or intermittent) 
• CS use within 30 
days 
• Use of potentially 
confounding meds 
• Clinically 
significant nasal d/o 
• URI within 14 
days 
• Serious comobidity  
• Pregnancy 
(current/plans/ 
breast feeding) 
within 30 days 
0 Noninhaled 
intranasal CO2 
gas admin’d 
at: 
5mL/s x 10s 
10mL/s x 10s 
5mL/s x 30s 
10mL/s x 30s 
per nostril 
from large-
capacity 
compressed 
gas cylinders 
TNSS = Total Nasal Symptom Score 
AR = allergic rhinitis 
CS = corticosteroid 
LTRA = leukotriene receptor antagonist 
URI = upper respiratory infection 
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OUTCOMES MEASURED 
All three studies measured improvement of nasal symptoms (nasal congestion, rhinorrhea, 
and sneezing) following treatment using data derived from participant feedback.  Casale et al. 
(2008) and Casale et al. (2011) measured nasal symptoms based on an ordinal scale from 0-5 (0, 
none; 1, little; 2, moderate; 3, quite a bit; 4, severe; 5, very severe).  Baroody et al. (2011) 
measured nasal congestion and rhinorrhea based on an ordinal scale from 0-3 (0, none; 1, mild; 2, 
moderate; 3, severe) as well as total number of sneezes.  In all three studies, Total Nasal 
Symptoms Scores (TNSS) were recorded by subjects before and after treatment to ultimately 
calculate mean change from baseline.  Mean change from baseline between arms provided the 
means for comparison to determine the intervention’s effectiveness. 
Both Casale et al. (2008) and Casale et al. (2011) subjected participants to an allergen 
nasal challenge, then provided time for them to mount an immune response (nasal symptoms) 
prior to administration of the treatment.  In this case, mean changes from baseline derived from 
before and after treatment symptom scores reflected the treatment's ability to induce 
symptomatic relief.  Alternatively, Baroody et al. (2011) subjected participants to the treatment 
first followed by the nasal allergen challenge.  In this case, mean changes from baseline reflected 
the treatment's ability to prevent nasal symptoms. 
Safety was determined by the incidence of adverse effects (if recorded) in each study.  
When possible, NNH was calculated using adverse event rate data and was considered along 
with the seriousness of these adverse events to help determine the safety of the intervention. 
RESULTS 
Efficacy 
Casale et al. (2008) studied adults with a positive skin prick test response to seasonal 
grass or mold allergens prevalent in Omaha, Nebraska in May 2005.  The authors reported 26.7% 
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of subjects who received CO2 treatment achieved TNSS improvement greater than 75% from 
baseline at 30 minutes after treatment compared to only 3.4% of subjects who received placebo 
(p = .009).  These values indicate a NNT equal to five to provide more than 75% relief of nasal 
symptoms. 
Baroody et al. (2011) studied adults with a positive skin prick test response to either grass 
or ragweed allergens.  The authors observed a clinically significant treatment effect (prevention) 
on sneezes as well as ipsilateral and contralateral nostril nasal symptoms after applying CO2 at 
8.33mL/s for 10 seconds per nostril. 
Table 2. Baroody et al. (2011) Mean Change of Nasal Symptoms from Baseline TNSS 
Parameter No-treatment Phase 
median (range) 
CO2-treatment Phase 
median (range) 
p-value 
Sneezes (no.) 2.0 (0-14) 0 (0-5) 0.05 
RN ipsi (score) 2.0 (0-6) 0.0 (0-4) 0.014 
RN con (score) 2.0 (0-5) 0.0 (0-4) 0.014 
SN ipsi (score) 2.0 (-1-6) 0.0 (-1-6) 0.1 
SN con (score) 2.0 (-1-6) 0.0 (-1-6) 0.07 
Ipsi = ipsilateral nostril to challenge; con = contralateral nostril to challenge; RN = runny nose; 
SN = stuffy nose. 
 
Casale et al. (2011) studied adults with a positive skin prick test response to either dust 
mite, cockroach, cat, dog, or mold allergens.  Study facilitators administered various dosages of 
CO2 (at 5 and 10mL/s flow rates per nostril applied for 10 and 30 second durations) compared to 
placebo.  When comparing mean changes from baseline, only one dosage (10mL/s/nostril x 10 
seconds) provided a statistically significant treatment effect (p = .03).  At 30 minutes after 
administration, susceptible subjects experienced peak symptom relief lasting at least four hours. 
Table 3. Casale et al. (2011): Mean Change of TNSS from Baseline per Dosage 
Experimental Arm: CO2 Dose Mean change from baseline TNSS p-value 
A: 5mL/s x 10s/nostril -4.36 p = .09 
B: 10mL/s x 10s/nostril  -4.69 p = .03 
C: 5mL/s x 30s/nostril -3.68 p = .86 
D: 10mL/s x 30s/nostril  -4.58 p = .19 
TNSS = Total Nasal Symptom Score 
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Safety 
Casale et al. (2008) reported that no “serious” or “medically significant” adverse events 
occurred during this study.  The most common adverse events that occurred included nasal 
stinging and watery eyes.  95% of experimental subjects experienced some degree of nasal 
stinging versus 44.8% of control subjects.  78.3% of experimental subjects experienced some 
degree of watery eyes compared to 27.6% of control subjects.  The NNH for either nasal stinging 
or watery eyes was equal to one.  Other adverse events reported by subjects included a 
nonspecific “swimmy feeling,” pharyngitis, headache, laryngitis, and stomach cramps.  The 
authors contend that adverse events occurred only during gas administration and ceased before 
gas administration was terminated.  Adverse events due to repeat treatments were not reported as 
only single-use treatment was studied. 
Baroody et al. (2011) reported that subjects experienced a temporary burning sensation 
during CO2 administration.  They reported that no other adverse effects resulted from the 
treatment.  Before the allergen challenge was presented to subjects, sneeze counts as well as 
nasal and eye symptoms were recorded at baseline and then again after treatment.  The change 
from baseline was recorded only after (but not during) gas administration.  Using the comparison 
of symptoms from before and after treatment, the authors reported that CO2 administration 
caused no significant adverse events (p > 0.05).  Adverse events due to repeat treatments were 
not reported as only single-use treatment was studied. 
Casale et al. (2011) reported the most common adverse events included nasal discomfort, 
headache and lacrimation – all of which resolved upon cessation of gas administration without 
intervention.  Other adverse events reported include rhinalgia, rhinorrhea, throat irritation, 
increased blood pressure, and dizziness.  The single most common adverse event reported in 
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Group B was nasal discomfort which was reported by 81.4% of subjects in the experimental 
group versus only 8.3% in the control group.  Nasal discomfort induced by the intervention 
demonstrates a NNH equal to one.  Adverse events due to repeat treatments were not reported as 
only single-use treatment was studied.  
Table 4. Casale et al. (2011): Most common adverse events in Group B (10mL/s/nostril x 10s) 
Adverse Event EER % (Group B) CER % (Placebo) NNH 
Nasal discomfort 81.4 8.3 1 
Lacrimation incr. 27.1 2.8 4 
Headache 8.6 13.9 -18 
Rhinalgia 8.6 2.8 17 
Rhinorrhea 2.9 2.8 1000 
Throat irritation 8.6 0.0 11 
Blood pressure incr. 1.4 5.6 -23 
Dizziness 2.9 0.0 34 
EER = experimental adverse event rate, CER = control adverse event rate, NNH = number 
needed to harm 
 
None of these studies reported any withdraw of subjects from participation due to 
intolerability to treatment adverse effects. 
DISCUSSION 
Demonstrating statistically significant effectiveness (p-value = .009) and a low NNT 
(five), Casale et al. (2008) was the only study examined in this review that was devoid of 
potentially confounding factors.  Maintenance of blinding measures or lack thereof proved to be 
the greatest limitation to the validity of Baroody et al. (2011) and Casale et al. (2011) as true 
RCTs.  While Casale et al. (2008) administered compressed room air to the control group, 
Baroody et al. (2011) and Casale et al. (2011) applied the physical apparatus without 
administering gas of any type.  Baroody et al. (2011) reported that neither researchers nor 
subjects were blinded to the knowledge of the phase of the two-way crossover in which they 
were participating.  Casale et al. (2011) reported being unclear whether blinding was preserved 
or lost.  Additionally, Casale et al. did not maintain intention-to-treat analysis.  If subjects did not 
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complete one or more symptom assessments, they were omitted from the analysis for that time 
point.  This may have exaggerated the strength of the treatment effect.  Statistically significant 
efficacy demonstrated by both Baroody et al. (2011) and Casale et al. (2011) must be viewed 
with consideration given to these potentially confounding elements. 
For the duration of these three studies, no subjects experienced any serious adverse 
events.  Similarly, none of the authors reported any fallout due to therapy intolerability.  Though 
the severity of adverse events following single-dose treatment may not have been great, NNH 
with regards to nasal stinging was equal to one.  NNH with regards to watery eyes ranged from 
one to four depending on the dose delivered.  These low numbers needed to harm indicate a high 
incidence of discomfort induced by a single dose of therapy.  Unfortunately, the high recurrence 
of symptoms experienced by many individuals who suffer from AR (especially seasonal AR) 
makes chronic use of such a rapid therapy more likely than one-time use.  Chronic use would 
further subjects users to these adverse effects and has not yet been studied. 
Carbon dioxide gas was administered in these studies by appropriate tubing attached to 
large-capacity compressed gas cylinders.  While this apparatus is not practical, Casale et al. 
(2008) cited a less cumbersome hand-held version currently being used for migraine treatment 
research that will be used in future studies.  At this time, noninhaled intranasal CO2 therapy is 
not commercially available as its use remains investigational.2  Treatment cost was not discussed 
in these articles. 
CONCLUSION 
At this time, the evidence is inconclusive to suggest that noninhaled intranasal carbon 
dioxide gas is a safe and effective treatment for nasal symptoms of AR.  Of these three studies, 
only Casale et al. (2008) maintained adequate blinding.  The lack of blinds in Baroody et al. 
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(2011) and Casale et al. (2008) may have confounded their data and consequently compromised 
the validity of their results.   Despite a promising treatment effect observed by Casale et al. 
(2008) supported by high quality research methods, these results must be reproduced before 
effectiveness can be concluded. 
Regarding safety of therapy, extremely low NNH for the most common adverse events 
(nasal stinging and watery eyes) indicate a very high incidence of these events experienced by 
subjects.  The fact that these adverse effects almost always ceased upon cessation of gas flow 
indicates low danger following single-use treatment.  However, despite this seemingly safe short-
term adverse event profile, chronic use must be studied to identify any new adverse events or 
worsening of nonserious adverse events over time (i.e. mucosal desiccation) before safety can be 
properly evaluated.  Recognition of adverse effects from repeated use would be necessary to 
more accurately assess the safety of this treatment.  
To assess the safety and efficacy of noninhaled intranasal CO2 gas compared to current 
available therapies that induce rapid symptomatic relief (i.e. oxymetazoline), these two therapies 
should be compared side-by-side in the same study.  Future studies should attempt to establish 
the safety of chronic use, the side effects of potential abuse (as is often seen with Afrin®), 
comparison with existing therapies including intranasal and oral antihistamines, and 
reproducibility of results with a standard dosage.   
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